The human hookworm vaccine

Vaccine

Volumn 31, Issue SUPPL2, 2013, Pages

  Hotez, Peter J ^a,b,c   Diemert, David ^a,b,d   Bacon, Kristina M ^e   Beaumier, Coreen ^a,b,c   Bethony, Jeffrey M ^a,b,d   Bottazzi, Maria Elena ^a,b,c   Brooker, Simon ^f   Couto, Artur Roberto ^g   da Silva Freire, Marcos ^g   Homma, Akira ^g   Lee, Bruce Y ^e   Loukas, Alex ^h   Loblack, Marva ^a,b   Morel, Carlos Medicis ^g   Oliveira, Rodrigo Correa ^g   Russell, Philip K ^a,b  

^a Sabin Vaccine Institute   (United States)

^b SABIN VACCINE INSTITUTE   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g INSTITUTO OSWALDO CRUZ   (Brazil)

^h JAMES COOK UNIVERSITY   (Australia)

Author keywords

Anemia; Helminth; Hookworm; Na APR 1; Na GST 1

Indexed keywords

ALUMINUM HYDROXIDE; ANTHELMINTIC AGENT; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; TOLL LIKE RECEPTOR AGONIST;

AFRICA; ASIA; BLEEDING; BRAZIL; DRUG FORMULATION; ENDEMIC DISEASE; ENERGY; HEALTH PROGRAM; HOOKWORM INFECTION; HUMAN; NECATOR AMERICANUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING;

ACADEMIES AND INSTITUTES; ANCYLOSTOMATOIDEA; ANIMALS; ANTIGENS, HELMINTH; BIOMEDICAL RESEARCH; CLINICAL TRIALS, PHASE I AS TOPIC; HOOKWORM INFECTIONS; HUMANS; PUBLIC SECTOR; PUBLIC-PRIVATE SECTOR PARTNERSHIPS; RECOMBINANT PROTEINS; TECHNOLOGY TRANSFER; TOLL-LIKE RECEPTOR 4; VACCINES; WORLD HEALTH;

EID: 84876813636     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.11.034     Document Type: Review

References (39)

1. Hotez P.J., Brooker S., Bethony J.M., Bottazzi M.E., Loukas A., Xiao S. Hookworm infection. N Engl J Med 2004, 351:799-807.
2. Hotez P.J., Fenwick A., Savioli L., Molyneux D.H. Rescuing the bottom billion through control of neglected tropical diseases. Lancet 2009, 373:1570-1575.
3. Hotez P.J., Molyneux D.H., Fenwick A., Ottesen E., Ehrlich Sachs S., Sachs J.D. Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 2006, 4:e277.
4. Smith J.L., Brooker S. Impact of hookworm infection and deworming on anaemia in non-pregnant populations: a systematic review. Trop Med Int Health 2010, 15:776-795.
5. Brooker S., Hotez P.J., Bundy D.A. Hookworm-related anaemia among pregnant women: a systematic analysis. PLoS Negl Trop Dis 2008, 2:e291.
6. Bleakley H. Disease and development: evidence from hookworm eradication in the American South. Q J Econ 2007, 122:73-117.
7. Brooker S., Clements A.C., Hotez P.J., Hay S.I., Tatem A.J., Bundy D.A., et al. The co-distribution of Plasmodium falciparum and hookworm among African schoolchildren. Malaria J 2006, 5:99.
8. Brooker S., Akhwale W., Pullan R., Estambale B., Clarke S.E., Snow R.W., et al. Epidemiology of plasmodium-helminth co-infection in Africa: population at risk, potential impact on anemia, and prospects for combining control. Am J Trop Med Hyg 2007, 77(6 Suppl.):88-98.
9. Hotez P.J., Bethony J.M., Diemert D.J., Pearson M., Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 2010, 8:814-826.
10. Hotez P. A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more. Health Aff (Millwood) 2011, 30:1080-1087.
11. Stoll N.R. This wormy world. J Parasitol 1947, 33:1-18.
12. Goud G.N., Deumic V., Gupta R., Brelsford J., Zhan B., Gillespie P., et al. Expression, purification, and molecular analysis of the Necator americanus glutathione S-transferase 1 (Na-GST-1): a production process developed for a lead candidate recombinant hookworm vaccine antigen. Protein Exp Purif 2012, 83:145-151.
13. Plieskatt J., Rezende W., Olsen C., Trefethen J., Joshi S.B., Middaugh C.R., et al. Advances in vaccines against neglected tropical diseases: enhancing physical stability of a recombinant hookworm vaccine through biophysical and formulation studies. Hum Vaccine Immunother 2012, 8. [Epub ahead of print].
14. Pearson M.S., Pickering D.A., Tribolet L., Cooper L., Mulvenna J., Oliveira L.M., et al. Neutralizing antibodies to the hookworm hemoglobinase Na-APR-1: implications for a multivalent vaccine against hookworm infection and schistosomiasis. J Infect Dis 2010, 201:1561-1569.
15. Pearson M.S., Bethony J.M., Pickering D.A., de Oliveria L.M., Jariwala A., Santiago H., et al. An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection. FASEB J 2009, 23:3007-3019.
16. Blount D., Hooi D., Feary J., Venn A., Telford G., Brown A., et al. Immunologic profiles of persons recruited for a randomized, placebo-controlled clinical trial of hookworm infection. Am J Trop Med Hyg 2009, 81:911-916.
17. Feary J.R., Venn A.J., Mortimer K., Brown A.P., Hooi D., Falcone F.H., et al. Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clin Exp Allergy 2010, 40:299-306.
18. Gaze S., McSorley H.J., Daveson J., Jones D., Bethony J.M., Oliveira L.M., et al. Characterising the mucosal and systemic immune responses to experimental human hookworm infection. PLoS Pathog 2012, 8:e1002520.
19. Tendler M., Simpson A.J. The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. Acta Trop 2008, 108:263-266.
20. Riveau G., Deplanque D., Remoue F., Schacht A.M., Vodougnon H., Capron M., et al. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl Trop Dis 2012, 6:e1704.
21. Loukas A., Bethony J., Brooker S., Hotez P. Hookworm vaccines: past, present, and future. Lancet Infect Dis 2006, 6:733-741.
22. McSorley H.J., Loukas A. The immunobiology of human hookworm infections. Parasite Immunol 2010, 32:549-559.
23. Diemert D.J., Pinto A.G., Freire J., Jariwala A., Santiago H., Hamilton R.G., et al. Generalized urticaria induced by the Na-ASP-2 hookworm vaccine: implications for the development of vaccines against helminths. J Allergy Clin Immunol 2012, 130:169076.e6.
24. Geiger S.M., Alexander N.D., Fujiwara R.T., Brooker S., Cundill B., Diemert D.J., et al. Necator americanus and helminth co-infections: further down-modulation of hookworm-specific type 1 immune responses. PLoS Negl Trop Dis 2011, 5:e1280.
25. McSorley H.J., Gaze S., Daveson J., Jones D., Anderson R.P., Clouston A., et al. Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS ONE 2011, 6:e24092.
26. Hotez P.J. Mass drug administration and integrated control for the world's high prevalence neglected tropical diseases. Clin Pharmacol Ther 2009, 85:659-664.
27. Molyneux D.H., Hotez P.J., Fenwick A. " Rapid-impact interventions" : how a policy of integrated control for Africa's neglected tropical diseases could benefit the poor. PLoS Med 2005, 2:e336.
28. [accessed 09.06.12]. http://www.unitingtocombatntds.org/downloads/press/ntd_event_london_decl aration_on_ntds.pdf.
29. Hotez P. Enlarging the " audacious goal" : elimination of the world's high prevalence neglected tropical diseases. Vaccine 2011, 29(Suppl. 4):D104-D110.
30. Keiser J., Utzinger J. Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis. JAMA 2008, 299:1937-1948.
31. Albonico M., Bickle Q., Ramsan M., Montresor A., Savioli L., Taylor M. Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ 2003, 81:343-352.
32. Soukhathammavong P.A., Sayasone S., Phongluxa K., Xayaseng V., Utzinger J., Vounatsou P., et al. Low efficacy of single dose albendazole and mebendazole against hookworm and effect on concomitant helminth infection in Lao PDR. PLoS Negl Trop Dis 2012, 6:e1417.
33. Albonico M., Smith P.G., Ercole E., Hall A., Chwaya H.M., Alawi K.S., et al. Rate of reinfection with intestinal nematodes after treatment of children with mebendazole or albendazole in a highly endemic area. Trans R Soc Trop Med Hyg 1995, 89:538-541.
34. World Health Organization. Prevention and control of schistosomiasis and soil-transmitted helminthiasis: report of a WHO Expert Committee 2002; WHO Technical Report Series 912.
35. Brooker S., Bethony J., Hotez P.J. Human hookworm infection in the 21st century. Adv Parasitol 2004, 58:197-288.
36. Thein-Hlaing, Than-Saw, Myat-Lay-Kyin. The impact of three-monthly age-targeted chemotherapy on Ascaris lumbricoides infection. Trans R Soc Trop Med Hyg 1991, 85:519-522.
37. Lee B.Y., Bacon K.M., Bailey R., Wiringa A.E., Smith K.J. The potential economic value of a hookworm vaccine. Vaccine 2011, 29:1201-1210.
38. Morel C.M., Acharya T., Bround D., Dangl A., Elias C., Ganguly N.K., et al. Health innovation networks to help developing countries address neglected diseases. Science 2005, 309:401-404.
39. [accessed 17.06.12]. http://www.dcvmn.com/.